Disease · MONDO_0000328
Comparisons in its trials12
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 12 of 12
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| PA21 vs Sevelamer Carbonate: serious adverse events | 78 of 391 | 52 of 267 | 658 | NCT01464190 | Trial comparisons |
| Tenapanor 30 mg BID vs Placebo: deaths from any cause | 0 of 117 | 0 of 119 | 236 | NCT03824587 | Trial comparisons |
| Tenapanor 30 mg BID vs Placebo: serious adverse events | 3 of 117 | 5 of 119 | 236 | NCT03824587 | Trial comparisons |
| Tenapanor 30 mg BID vs Placebo: s-P Response at Week 4 | 43 of 116 | 26 of 119 | 235 | NCT03824587 | Trial comparisons |
| PA21 vs Sevelamer Hydrochloride: deaths from any cause | 0 of 108 | 0 of 105 | 213 | NCT01850602 | Trial comparisons |
| PA21 vs Sevelamer Hydrochloride: serious adverse events | 6 of 108 | 5 of 105 | 213 | NCT01850602 | Trial comparisons |
| Renvela vs Placebo: deaths from any cause | 0 of 101 | 0 of 101 | 202 | NCT03001011 | Trial comparisons |
| Renvela vs Placebo: serious adverse events | 26 of 101 | 31 of 101 | 202 | NCT03001011 | Trial comparisons |
| Calcium Acetate Oral Solution vs Sevelamer Carbonate: serious adverse events | 2 of 38 | 1 of 38 | 76 | NCT01427907 | Trial comparisons |
| Ferric Citrate - Hemodialysis vs Ferric Citrate - Peritoneal Dialysis: deaths from any cause | 0 of 27 | 0 of 27 | 54 | NCT03079869 | Trial comparisons |
| Ferric Citrate - Hemodialysis vs Ferric Citrate - Peritoneal Dialysis: serious adverse events | 7 of 27 | 10 of 27 | 54 | NCT03079869 | Trial comparisons |
| Chewed Lanthanum Carbonate vs Crushed Lanthanum Carbonate: serious adverse events | 1 of 11 | 2 of 11 | 22 | NCT00660530 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0000328/comparisons